Define Ventures Welcomes Carolyn Magill as New Partner
The dynamic landscape of health technology sees a significant shift as Carolyn Magill steps into the role of venture partner at Define Ventures. With a remarkable background as former CEO of Aetion and Remedy Partners, she brings over 25 years of valuable expertise to the table. Her appointment is a strategic move to bolster innovation across provider, payer, and pharmaceutical sectors.
A Leader in Healthcare Innovation
Carolyn Magill's extensive career is decorated with leadership roles that span multiple segments of the healthcare ecosystem. Prior to her role at Define Ventures, Magill was instrumental in steering Aetion, which specializes in converting real-world data into regulatory-grade insights. Her previous position as CEO of Remedy Partners also positioned her at the forefront of bundled payments solutions, showcasing her ability to drive progress in complex healthcare settings.
Transforming Healthcare with Data-Driven Solutions
At Aetion, Carolyn focused sharply on leveraging data to form evidence for critical healthcare decisions, which aligns perfectly with the overarching goals of Define Ventures. Her adeptness in fostering collaboration among various stakeholders in the healthcare industry will serve as a cornerstone for the firm as it seeks to support innovative solutions.
Strategic Guidance for Emerging Companies
According to Lynne Chou O'Keefe, founder and managing partner at Define Ventures, "Carolyn's extensive experience across payer, provider, and pharmaceutical sectors makes her uniquely qualified to guide the next generation of health tech innovators." This sentiment reinforces the strategic direction Define Ventures aims to pursue under her leadership.
Empowering Founders to Innovate
Magill herself expressed enthusiasm about her new role, stating that joining Define Ventures offers her a platform to influence early-stage health tech innovation profoundly. She emphasized the importance of collaborative efforts within the healthcare space, highlighting that her work will now focus on helping founders transform their ideas into impactful solutions.
Building a Robust Leadership Team
Carolyn joins a distinguished group of venture partners at Define Ventures, including Bruce Broussard, the former CEO of Humana, and Frank Williams, co-founder of Evolent Health. This trio of esteemed industry leaders enriches the strategic depth available to partner companies, enhancing their potential to thrive in a competitive marketplace.
Define Ventures: A Leading Force in Health Tech
With $800 million in assets under management, Define Ventures stands as one of the largest venture capital firms dedicated to early-stage health tech companies. Their investment philosophy prioritizes partnerships with entrepreneurs at seed, series A, and series B stages, fostering the development of groundbreaking solutions in the healthcare arena.
Define Ventures has paved the way for numerous health tech entrepreneurs, employing a targeted approach that emphasizes high conviction partnerships. The firm has collaborated with a range of companies like Hims & Hers (NYSE: HIMS), further demonstrating its commitment to innovation. Together with leaders like Magill, Define Ventures is poised to make a substantial impact.
About Define Ventures
Define Ventures specializes in nurturing early-stage health tech companies, promoting a high conviction approach to partnership. Their vision embodies the transformation of healthcare, led by a blend of technological insight and a deep understanding of the healthcare landscape. The team's track record includes significant exits, with previous successes generating over $25 billion, which includes names like Livongo (NYSE: LVGO) and Evolent (NYSE: EVH).
Frequently Asked Questions
Who is Carolyn Magill?
Carolyn Magill is the newly appointed venture partner at Define Ventures, with a notable background as the previous CEO of Aetion and Remedy Partners.
What does Define Ventures focus on?
Define Ventures is focused on early-stage health tech companies and aims to foster innovation in the healthcare sector through strategic partnerships.
What is the mission of Define Ventures?
The mission of Define Ventures is to define the future of healthcare by supporting companies with deep expertise and technology-driven mindsets.
How much capital does Define Ventures manage?
Define Ventures manages $800 million in assets and invests in health tech companies at the seed, series A, and series B stages.
Who are other partners at Define Ventures?
Other partners at Define Ventures include Bruce Broussard, ex-CEO of Humana, and Frank Williams, co-founder of Evolent Health.
